中国神经再生研究(英文版)

中国神经再生研究(英文版) ›› 2014, Vol. 9 ›› Issue (20): 1830-1838.doi: 10.4103/1673-5374.143431

• 原著:脊髓损伤修复保护与再生 • 上一篇    下一篇

奥罗莫星联合骨形态发生蛋白4修复急性脊髓挫伤：可发挥优势叠加

  

  • 收稿日期:2014-08-22 出版日期:2014-10-25 发布日期:2014-10-25
  • 基金资助:

    十一五计划项目(2012BAI34B02)

Synergistic actions of olomoucine and bone morphogenetic protein-4 in axonal repair after acute spinal cord contusion

Liang Chen 1, 2, Jianjun Li 1, 2, 3, Liang Wu 4, Mingliang Yang 1, 2, 3, Feng Gao 1, 2, Li Yuan 5   

  1. 1 Capital Medical University School of Rehabilitation Medicine, Beijing, China
    2 Department of Spinal and Neural Function Reconstruction, China Rehabilitation Research Center, Beijing, China
    3 Center of Neural Injury and Repair, Beijing Institute for Brain Disorders, Beijing, China
    4 Rehabilitation Center, Beijing Xiaotangshan Rehabilitation Hospital, Beijing, China
    5 Department of General Surgery, China Rehabilitation Research Center, Beijing, China
  • Received:2014-08-22 Online:2014-10-25 Published:2014-10-25
  • Contact: Jianjun Li, M.D., Department of Spinal Cord Neurological Reconstruction, Beijing Boai Hospital, China Rehabilitation Research Center, Beijing 100068, China, lcrrc9@gmail.co
  • Supported by:

    This work was supported by a grant from the ‘Twelve Five-year Plan’ for Science & Technology Research of China, No. 2012BAI34B02.

PDF

900

摘要：

奥罗莫星与骨形态发生蛋白4联合应用是否会产生1+1>2的效果？为验证该假设，实验运用NYU打击器纵向撞击大鼠脊髓T8节段建立急性脊髓挫伤模型，在损伤部位周围注射骨形态发生蛋白4细胞悬液和/或腹腔注射奥罗莫星。结果显示，奥罗莫星不影响骨形态发生蛋白4缩小脊髓空洞的效果，且可有效抑制星形胶质细胞增殖和瘢痕形成；联合骨形态发生蛋白4后该作用无协同增强。当两药联合使用后，大鼠运动功能恢复显著。说明两者联合使用是各取所长，且不抵冲各自的优势，为神经再生创造更好的条件，更加有利于脊髓损伤的修复。

关键词: 神经再生, 脊髓损伤, Olomoucine, 胶质限制前体细胞源性星形胶质细胞, 胶质瘢痕, 空洞, 轴突再生

Abstract:

To determine whether olomoucine acts synergistically with bone morphogenetic protein-4 in the treatment of spinal cord injury, we established a rat model of acute spinal cord contusion by impacting the spinal cord at the T8 vertebra. We injected a suspension of astrocytes derived from glial-restricted precursor cells exposed to bone morphogenetic protein-4 (GDAsBMP) into the spinal cord around the site of the injury, and/or olomoucine intraperitoneally. Olomoucine effectively inhibited astrocyte proliferation and the formation of scar tissue at the injury site, but did not prevent proliferation of GDAsBMP or inhibit their effects in reducing the spinal cord lesion cavity. Furthermore, while GDAsBMP and olomoucine independently resulted in small improvements in locomotor function in injured rats, combined administration of both treatments had a significantly greater effect on the restoration of motor function. These data indicate that the combined use of olomoucine and GDAsBMP creates a better environment for nerve regeneration than the use of either treatment alone, and contributes to spinal cord repair after injury.

Key words: nerve regeneration, spinal cord injury, olomoucine, glial-restricted precursor-derived astrocytes, glial scar, cavity, axonal regeneration, neural regeneration